63211-98-3

Usage

Uses

Used in Oncology:
2-Chloro-6-methylpyrimidine-4,5-diamine is used as a targeted therapy for patients with TRK fusion-positive cancer. It is particularly effective in treating various solid tumors that harbor NTRK gene fusions, due to its high specificity in inhibiting tropomyosin receptor kinases (TRKs). This leads to the suppression of cancer cell growth and the induction of apoptosis, offering a potential treatment option for patients with TRK fusion-positive malignancies.
Used in Drug Development:
2-Chloro-6-methylpyrimidine-4,5-diamine serves as a key component in the development of novel cancer therapies. Its unique ability to target TRKs with high specificity makes it a valuable asset in the creation of new drugs that can effectively combat cancer cells while minimizing damage to healthy cells. This targeted approach has the potential to improve treatment outcomes and reduce side effects associated with traditional chemotherapy.
Used in Research:
2-Chloro-6-methylpyrimidine-4,5-diamine is utilized in various research applications to better understand the mechanisms of cancer cell growth and the role of TRKs in tumor development. By studying the interactions between 2-Chloro-6-methylpyrimidine-4,5-diamine and its target proteins, researchers can gain valuable insights into the molecular pathways involved in cancer progression and identify potential therapeutic targets for the development of new anti-cancer agents.

InChI:InChI=1/C5H7ClN4/c1-2-3(7)4(8)10-5(6)9-2/h7H2,1H3,(H2,8,9,10)

Upstream product

• 5453-06-5 4-Amino-5-nitro-6-methyl-2-chloropyrimidine 
• 7647-01-0 hydrogenchloride 
• 13162-26-0 2,4-dichloro-6-methyl-5-nitropyrimidine 

Downstream Products

• 1681-19-2 2-chloro-6-methyl-7(9)H-purine 
• 1681-19-2 2-chloro-6-methyl-9H-purine 
• 10179-83-6 7-methyl-1H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 39209-57-9 6-methyl-7,9-dihydro-purin-8-one 
• 1075-29-2 6-methyl-7,9-dihydro-purine-8-thione 
• 2004-03-7 6-methylpurine 
• 225100-00-5 4-[[9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurine]-2-yl-3-oxypropyl]pyridine N-oxide 
• 225099-81-0 9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethyl-2-[3-(4-pyridyl)propyloxy]purine 
• 225100-12-9 2-chloro-9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurine 

Relevant academic research and scientific papers

Methylated Nucleobases: Synthesis and Evaluation for Base Pairing In Vitro and In Vivo

The synthesis, base pairing properties and in vitro (polymerase) and in vivo (E. coli) recognition of 2′-deoxynucleotides with a 2-amino-6-methyl-8-oxo-7,8-dihydro-purine (X), a 2-methyl-6-thiopurine (Y) and a 6-methyl-4-pyrimidone (Z) base moiety are described. As demonstrated by Tm measurements, the X and Y bases fail to form a self-complementary base pair. Despite this failure, enzymatic incorporation experiments show that selected DNA polymerases recognize the X nucleotide and incorporate this modified nucleotide versus X in the template. In vivo, X is mainly recognized as a A/G or C base; Y is recognized as a G or C base and Z is mostly recognized as T or C. Replacing functional groups in nucleobases normally involved in W?C recognition (6-carbonyl and 2-amino group of purine; 6-carbonyl of pyrimidine) readily leads to orthogonality (absence of base pairing with natural bases).